author-photo

Alessandra Bearz

National Institutes of Health

241

Papers

9904

Citations

Citation Trend

Filter By

Papers (173) Sort By

Journal Conference Others

PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow up of efficacy results from the randomized phase II RESORT trial.

2021 Expert Review of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (1)
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
1196P Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.

2021 in Vivo
Show All
- Source
- Cite
- Save
Citations (0)
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer

2020 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (3)
1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)